Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology ... Successful completion of the Phase 2 trials could pave the way for Phase 3 studies and accelerate BMF-219's path to market.

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

A new analysis revealed that Medicare spent roughly $2 billion over three years on unnecessary back surgeries for older adults. This alarming figure comes from research conducted by the nonpartisan ...

About TX45, a long-acting Fc-relaxin fusion protein TX45 is an Fc-relaxin fusion protein ... including the ongoing Phase 1b and Phase 2 clinical trials for TX45 in Group 2 PH-HFpEF; and the potential ...

Theradaptive, a privately held, clinical stage biologics company developing targeted protein therapeutics for spine, orthopedics, soft tissue repair and targeted immuno-oncology, today announced the ...

During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ ...

During the quarter Genmab's GEN1057, an investigational proprietary bispecific antibody and Merck KGaA's M5542, which is a ...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regu ...

Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, ...

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or ... lifted the clinical hold on the ongoing Phase 1/2 clinical trials in type 2 and type 1 diabetes (COVALENT-111 and ...